Evaluation of methylated DCR1 as a biomarker for response to adjuvant irinotecan-based therapy in stage III colon cancer: cancer and leukaemia Group B 89803 (Alliance)

Aberrantly methylated genes contribute to the landscape of epigenetic alterations in colorectal adenocarcinoma. The global CpG Island methylator phenotype (CIMP) and individually methylated genes are potential prognostic/predictive biomarkers. Research suggests an association between methylated DCR1...

Full description

Bibliographic Details

Published in:	Epigenetics
Main Authors:	Lynn Symonds, Ming Yu, YuHong Zhang, Fang-Shu Ou, Tyler J. Zemla, Kelly Carter, Monica Bertagnolli, Federico Innocenti, Linda JW Bosch, Gerrit A Meijer, Beatriz Carvalho, William M. Grady, Stacey A. Cohen
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2022-12-01
Subjects:	calgb 89803 (alliance) epigenetic factors dcr1 dna methylation biomarker stage 3 colon cancer response to irinotecan
Online Access:	http://dx.doi.org/10.1080/15592294.2022.2058225